---
document_datetime: 2023-09-21 18:52:05
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/daxas-epar-all-authorised-presentations_en.pdf
document_name: daxas-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.1997563
conversion_datetime: 2025-12-27 09:51:50.258309
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging    | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|------------------------|-------------|
| EU/1/10/636/001  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 10 tablets  |
| EU/1/10/636/002  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 30 tablets  |
| EU/1/10/636/003  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 90 tablets  |
| EU/1/10/636/004  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 14 tablets  |
| EU/1/10/636/005  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 28 tablets  |
| EU/1/10/636/006  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 84 tablets  |
| EU/1/10/636/007  | Daxas             | 500 µg     | Film-coated tablet    | Oral use                  | blister (PVC/PVDC/alu) | 98 tablets  |
| EU/1/10/636/008  | Daxas             | 250 µg     | Tablet                | Oral use                  | blister (PVC/PVDC/alu) | 28 tablets  |